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Genome-wide association study identiﬁes 14 novel
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Basal cell carcinoma (BCC) is the most common cancer worldwide with an annual incidence
of 2.8 million cases in the United States alone. Previous studies have demonstrated an
association between 21 distinct genetic loci and BCC risk. Here, we report the results of a two-
stage genome-wide association study of BCC, totalling 17,187 cases and 287,054 controls.
We conﬁrm 17 previously reported loci and identify 14 new susceptibility loci reaching
genome-wide signiﬁcance (Po5 108, logistic regression). These newly associated SNPs
lie within predicted keratinocyte regulatory elements and in expression quantitative trait loci;
furthermore, we identify candidate genes and non-coding RNAs involved in telomere
maintenance, immune regulation and tumour progression, providing deeper insight into the
pathogenesis of BCC.
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W
ith 2.8 million new cases diagnosed annually in the
United States1, basal cell carcinoma (BCC) is the
most common cancer worldwide and contributes
substantially to morbidity. BCC risk has been associated with
ultraviolet (UV) exposure, fair skin, arsenic exposure, ionizing
radiation, chronic immunosuppression, male gender and age1.
Since 2008, six population-based genome-wide association studies
(GWAS) of BCC have been reported identifying 16 regions
of susceptibility2–7. Candidate gene studies have identiﬁed ﬁve
additional pigmentation loci associated with BCC, including
IRF4, SLC45A2, RALY, TYR and OCA27. Here, we report the
largest-to-date two-stage genome-wide association meta-analysis
for BCC totalling 17,187 cases and 287,054 controls. The results
of this study conﬁrm 12 of 16 loci from prior GWAS, along with
5 of 5 loci from previous candidate gene studies, and identify
14 novel susceptibility loci for BCC.
Results
Stage 1 consisted of 12,945 self-reported BCC cases and 274,252
controls of European ancestry from 23andMe research partici-
pants (Supplementary Table 1). Validation of self-reported
surveys with adjudicated medical records revealed a sensitivity
and speciﬁcity of 93% and 99%, respectively (Supplementary
Table 2), indicating a misclassiﬁcation rate of less than 10%.
Simulation analysis demonstrated that this misclassiﬁcation rate
only modestly reduced the power to detect associations in this
study (Supplementary Fig. 1). Stage 2 consisted of an independent
GWAS cohort of 4,242 BCC cases and 12,802 controls of
European ancestry from the Nurses’ Health Study and Health
Professionals Follow-Up Study (Supplementary Table 1). Subse-
quently, meta-analysis of stages 1 and 2 was performed, encom-
passing 17,187 cases and 287,054 controls (Supplementary
Table 1). Further information on methodology and imputation
quality control is presented in the Online Methods, Supple-
mentary Tables 3-5, and Supplementary Figs 2–7.
Stage 1 analysis. Twenty-eight index single nucleotide poly-
morphisms (SNPs) were associated with BCC at the genome-wide
signiﬁcance level (Po5.0 10 8, logistic regression) in stage 1
and are depicted in the Manhattan plot (Fig. 1). Subset analysis
revealed relatively consistent effect sizes across age and gender for
these 28 SNPs (Supplementary Tables 6–7, Supplementary Fig. 8).
Interestingly, slightly larger effect sizes tended to occur in
younger cases, suggesting that other risk factors may play an
increasing role with age. As 10% of the BCC cases in our stage 1
cohort subsequently developed melanoma, we also investigated
whether the co-occurrence of melanoma contributed to the
observed associations with BCC risk. We therefore computed
association tests for the stage 1 index SNPs in BCC cases with and
without melanoma. All 28 SNPs displayed consistent effect sizes
across the two groups (Table 1, Supplementary Fig. 9), indicating
that they are independently associated with BCC susceptibility.
Stage 2 and combined meta-analysis. Twenty of the 28 index
SNPs were replicated in the stage 2 analysis (Po0.05, logistic
regression). While some loci did not reach statistical signiﬁcance
in stage 2, their 95% conﬁdence intervals (for odds ratios)
overlapped with the corresponding stage 1 conﬁdence intervals.
Meta-analysis of stages 1 and 2 identiﬁed a total of 31 loci
reaching genome-wide signiﬁcance (Po5 10 8, logistic
regression) for association with BCC. Among these 31 loci, 17 are
previously reported (Supplementary Tables 8–12). The remaining
14 are novel BCC susceptibility loci (Table 2, Supplementary
Table 13). Forest plots and regional association plots for these
14 SNPs are provided in Supplementary Figs 10–12. Of these 14
novel risk variants, 10 reached genome-wide signiﬁcance in
stage 1 and 4 reached genome-wide signiﬁcance in the combined
meta-analysis. As many pigmentation loci have been associated
with BCC susceptibility, we adjusted for pigmentation phenotype
in our stage 2 cohort and did not observe a signiﬁcant difference
between adjusted and unadjusted results for the 14 novel risk
variants (Supplementary Table 14).
Heritability of BCC and gene expression analysis. To measure
the proportion of BCC heritability that can be attributed to these
SNPs, we calculated the familial relative risk for BCC as outlined
by the Cancer Oncological Gene-Environment Study. Overall,
10.98% of familial relative risk for BCC is explained by the 31
genome-wide signiﬁcant loci; of this percentage, the 14 novel
susceptibility loci account for 2.62%. To further explore the role
of these 14 loci in BCC pathogenesis, we evaluated expression
levels of nearby genes in BCC tissue using two data sets from the
Gene Expression Omnibus (GEO) (GSE53462 and GSE7553).
Three loci demonstrated signiﬁcant differential gene expression
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Figure 1 | Manhattan plot of stage 1 GWAS analysis of BCC from 23andMe data set. Total stage 1 GWAS analysis included 12,945 cases and 274,252
controls. Loci with smallest Po106 (28 total, logistic regression) are labelled with the name of the nearest gene. Positions with Po5 10 8 (genome-
wide signiﬁcance) are shown in red. In stage 1, ten novel BCC susceptibility loci reached genome-wide signiﬁcance after adjusting for genomic control, all of
which are labelled in the ﬁgure with asterisks: from left to right, 3p13 (FOXP1), 3q28 (LPP), 6p21.32 (HLA-DQA2), 6p21.33 (HLA-B), 7p12.3 (TNS3), 7q22.1
(CUX1), 8q21.13 (ZBTB10), 9p22.2 (near BNC2), 19p13.3 (PLIN3), 21q22.3 (LINC00111). Four additional novel susceptibility loci—6p21.3 (NEU1), 10q24.3
(OBFC1), 6q27 (MIR3939), 6p22.3 (CASC15)—were genome-wide signiﬁcant in the overall meta-analysis (Table 2) and thus are not labelled in the ﬁgure.
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in BCC relative to normal skin: 3p13 FOXP1, 7p12.3 TNS3 and
6p22.3 CASC15 (Fig. 2, Po0.05, linear models for microarray
analysis).
Gene-environment interaction analysis. Ultraviolet exposure
and pigmentation phenotypes have been associated with BCC
risk and may interact with genetic variants to confer BCC suscep-
tibility. To further explore the inﬂuence of such factors on
our study, we tested for interactions between all 31 signiﬁcant
loci and UV exposure, hair colour, number of sunburns and
tanning ability (Supplementary Table 15). This analysis revealed
only one signiﬁcant interaction, between rs191177147 (LPP)
and hair colour. Additional testing in three separate hair colour
Table 1 | Interaction of 28 genome-wide signiﬁcant BCC associations in stage 1 with melanoma.
SNP Gene Neffect NSE NP Yeffect YSE YP Int P
rs12203592 IRF4 0.397 0.017 5.4 10 117 0.454 0.060 4.5 10 14 0.040
rs1805007 MC1R 0.321 0.023 8.8 1041 0.272 0.077 4.7 104 0.286
rs214785 TGM3 0.197 0.017 1.7 10 29 0.044 0.065 5.0 10 1 0.213
rs35407 SLC45A2 0.483 0.053 1.1 10 22 0.537 0.239 2.0 10 2 0.751
rs6059655 RALY 0.219 0.024 5.7 10 19 0.141 0.082 8.5 10 2 0.088
rs57142672 RCC2 0.128 0.014 1.2 10 18 0.214 0.052 4.4 10 5 0.612
rs73635312 GATA3 0.189 0.021 3.5 10 20 0.109 0.074 1.4 10 1 0.047
rs1126809 TYR 0.126 0.015 2.3 10 16 0.070 0.053 1.8 10 1 0.521
rs421284 CLPTM1L 0.138 0.014 1.1 10 22 0.046 0.050 3.5 10 1 0.783
rs2080303 ALS2CR12/CASP8 0.122 0.016 1.1 10 14 0.068 0.057 2.3 10 1 0.425
rs61824911 RHOU 0.139 0.016 9.3 10 18 0.023 0.061 7.1 10 1 0.300
rs2116709 FOXP1/EIF4E3 0.116 0.015 1.3 10 14 0.061 0.054 2.6 10 1 0.136
rs12916300 OCA2/HERC2 0.142 0.019 9.7 10 15 0.024 0.067 7.2 10 1 0.761
rs141115006 RGS22 0.143 0.020 3.1 10 13 0.077 0.071 2.8 10 1 0.819
rs10810657 BNC2 0.108 0.014 7.2 10 14 0.078 0.052 1.4 10 1 0.986
rs10093547 ZFHX4 0.219 0.031 5.1 10 13 0.147 0.106 1.6 10 1 0.755
rs191177147 LPP 0.114 0.016 6.3 10 13 0.009 0.057 8.8 10 1 0.517
rs9275642 HLA-DQB1/DQA2 0.123 0.019 2.4 10 11 0.080 0.065 2.2 10 1 0.346
rs7874604 CDKN2B 0.098 0.015 1.6 10 10 0.095 0.055 8.5 10 2 0.591
rs11170164 KRT5 0.163 0.025 1.2 10 10 0.134 0.094 1.6 10 1 0.303
rs73183643 CUX1 0.109 0.017 1.1 10 10 0.067 0.060 2.6 10 1 0.391
rs11993814 ZBTB10 0.097 0.016 2.1 10 9 0.146 0.058 1.2 10 2 0.413
rs2776353 LINC00111 0.092 0.015 1.5 10 9 0.063 0.055 2.5 10 1 0.623
rs1765871 ATP11A 0.068 0.014 1.1 106 0.145 0.052 4.8 10 3 0.981
rs10425559 TICAM1/PLIN3 0.086 0.014 2.7 109 0.004 0.052 9.3 10 1 0.458
rs1050529 HLA-B 0.106 0.019 2.5 108 0.096 0.069 1.7 10 1 0.486
rs7776701 TNS3 0.081 0.014 6.9 10 9 0.041 0.050 4.1 10 1 0.711
rs78097823 TTC28 0.164 0.034 2.4 10 6 0.354 0.120 3.5 10 3 0.466
Results generated from logistic regression models ﬁt separately in melanoma controls (N) and cases (Y). Includes P-value (Int P) from a likelihood ratio test for adding an interaction with melanoma
status to the GWAS model. Of the 274,252 BCC controls, 3138 were melanoma cases and 268,282 were melanoma controls. Of the 12,945 BCC cases, 1,350 were melanoma cases and 11,465 were
melanoma controls.
Table 2 | Fourteen novel loci reaching genome-wide signiﬁcance in two-stage GWAS of BCC.
SNP Region Gene Maj/min MAF (avg imp r2) P OR P OR P OR
rs2116709 3p13 FOXP1 A/T 0.40 (0.91) 7.9 10 15 0.89 6.1 104 0.91 2.3 10 17 0.90
rs10810657 9p22.2 BNC2 A/T 0.41 (0.98) 5.1 10 14 0.90 5.7 10 5 0.90 1.5 10 17 0.90
rs191177147 3q28 LPP G/T 0.39 (0.80) 3.2 10 12 1.11 1.0 10 3 1.10 1.2 10 14 1.11
rs9275642 6p21.32 HLA-DQA2 C/T 0.21 (0.89) 1.2 10 11 0.89 2.7 10 2* 0.81 2.4 10 12 0.89
rs73183643 7q22.1 CUX1 G/A 0.24 (0.96) 8.5 10 11 0.90 2.3 104 0.89 1.5 10 13 0.90
rs11993814 8q21.13 ZBTB10 C/T 0.26 (1.0) 2.8 10 10 0.91 4.5 10 2 0.94 8.8 10 11 0.92
rs2776353 21q22.3 LINC00111 A/T 0.33 (0.96) 5.0 10 10 0.91 7.7 104 0.91 1.6 10 12 0.91
rs10425559 19p13.3 PLIN3 G/A 0.40 (0.97) 3.8 10 9 0.92 8.4 10 1 0.99 2.8 10 8 0.93
rs1050529 6p21.33 HLA-B C/T 0.25 (0.71) 4.6 109 0.90 2.7 10 1w 0.89 2.6 10 9 0.90
rs7776701 7p12.3 TNS3 C/T 0.48 (0.98) 5.3 10 9 0.93 5.1 10 1 0.98 4.2 108 0.94
rs9267650 6p21.3 NEU1 A/T 0.05 (0.98) 2.4 108 1.18 2.0 10 1 1.09 1.1 10 8 1.17
rs7907606 10q24.3 OBFC1 T/G 0.17 (0.96) 7.4 108 1.10 2.4 10 2 1.08 4.7 109 1.10
rs4710154 6q27 MIR3939 A/T 0.32 (0.93) 8.1 108 1.08 4.3 10 2 1.06 1.1 10 8 1.08
rs2294214 6p22.3 CASC15 A/C 0.32 (0.95) 2.6 10 5 1.06 5.9 10 5 1.13 3.1 108 1.07
SNPs that met genome-wide signiﬁcance (Po5 10 8, via logistic regression) in overall meta-analysis are listed; these SNPs have not been associated with BCC in previous GWAS reports. Additionally,
we report genetic locus, nearest genes, major allele, minor allele, minor allele frequency (MAF) as calculated from stage 1 data, average imputation r2 (a measure of imputation quality) for stage 1, and
odds ratio (OR) with P-value for each stage, calculated with respect to the minor allele. In stage 1, we analysed 12,945 BCC cases and 274,252 controls. Stage 2 included 4242 BCC cases and 12,802
controls from NHS. We then combined data from stage 1 and stage 2 (which resulted in 17,187 BCC cases and 287,054 controls) and performed ﬁxed-effect meta-analysis. Statistics for effect
heterogeneity (Phet and I
2) are included in Supplementary Table 13. All subjects were from the US and of European ancestry.
*Genotyping results in stage 2.
wGenotyping results in stage 2. rs9266772 is used as proxy SNP for rs1050529 (r2¼0.569, D0 ¼0.771).
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groups demonstrated that rs191177147 signiﬁcantly interacted
with the light brown and dark brown/black hair groups (Table 3,
P¼ 2.9 10 6, logistic regression).
Discussion
The 14 novel susceptibility loci cluster into ﬁve functional
categories: telomere biology, immune regulation, tumour pro-
gression, non-coding RNA and pigmentation.
Variants within the TERT locus have previously been associ-
ated with BCC susceptibility, thus implicating telomere regulation
in BCC development8. Here, we identify a novel BCC suscepti-
bility locus, OBFC1, that is also involved in telomere
maintenance. rs7907606 at 10q24.3 (P¼ 4.7 10 9, odds ratio
(OR)¼ 1.10, logistic regression) lies 3 kb upstream of the OBFC1
gene, a member of the heterotrimer CST complex8. This complex
restricts telomere extension by binding telomeric DNA and
disrupting the ability of other proteins to recruit telomerase9.
Variants in the OBFC1 locus have been associated with mean
leukocyte telomere length8,10. rs7907606 is in linkage disequili-
brium (LD) with four of these variants (Supplementary Table 16),
including rs4387287 (r2¼ 0.98, D0 ¼  1.00), which lies within
the promoter of OBFC1 and is an eQTL for this gene in
sun-exposed skin (P¼ 8.3 10 6, GTEx V6 analysis)11. Though
widely studied, the connection between telomere length and
cancer is context dependent, as both long and short telomeres are
linked to malignancy12. This discrepancy is readily apparent in
the context of skin cancer, where longer telomeres are associated
with melanoma and shorter telomeres are associated with BCC12.
Our results further implicate telomere homeostasis in BCC
pathogenesis.
We also identiﬁed six novel susceptibility loci associated with
immune regulation. Two SNPs, rs1050529 and rs9275642, are in
human leukocyte antigen (HLA) regions. rs1050529 at 6p21.33
(P¼ 2.6 10 9, OR¼ 0.90, logistic regression) lies within an
exon of HLA-B, and leads to a non-conservative amino acid
substitution (A65T). rs1050529 has predicted enhancer and
promoter activity in keratinocytes and is an eQTL in six tissues.
Variants in HLA-B have been associated with a range of
autoimmune conditions, including vitiligo and psoriasis13,14.
HLA-B encodes the heavy chain component of major
histocompatibility complex (MHC) class I molecules, which
present endogenously synthesized peptides to cytotoxic T cells.
Downregulation of MHC class I molecules is a feature of many
types of cancers, which is thought to enable tumour cells to evade
recognition and destruction by T cells15. An analysis of 91 human
melanoma cell lines revealed decreased expression of class I
molecules in 67% of the cell lines, with HLA-B being the most
common16. The second HLA SNP reaching genome-wide
signiﬁcance was rs9275642 at 6p21.32 (P¼ 2.4 10 12,
OR¼ 0.89, logistic regression), which is located 24 kb upstream
of HLA-DQA2. This SNP is in tight LD with rs9275640 (r2¼ 0.89,
D0 ¼ 0.99), which is an eQTL for this gene in sun-exposed skin
(P¼ 3.6 10 6, GTEx V6 analysis)11. HLA-DQA2 variants are
also associated with autoimmune diseases, including type 1
diabetes, rheumatoid arthritis and alopecia areata14. These
ﬁndings represent the ﬁrst genome-wide signiﬁcant association
between MHC genes and BCC risk.
The third immune-related SNP, rs191177147 at 3q28 (P¼
9.8 10 17, OR¼ 1.11, logistic regression), resides within an
intron of LPP and is in LD with rs1464510 (r2¼ 0.54) and
rs9860547 (r2¼ 0.68, Supplementary Table 17); the former is
associated with autoimmune diseases such as celiac disease,
rheumatoid arthritis, juvenile idiopathic arthritis and vitiligo17–19,
while the latter is associated with allergy20. LPP encodes an
intracellular protein that shuttles between the cell membrane and
the nucleus, where it interacts with transcription factors to
modulate gene expression21. LPP overexpression has been
reported in squamous cell lung carcinomas and primary
sarcomas21. We also found an association between rs191177147
and hair colour, suggesting that this SNP may also contribute to
BCC risk by altering pigmentation phenotypes.
Another SNP with potential signiﬁcance in immune regulation
is rs10425559 at 19p13.3 (P¼ 2.9 10 9, OR¼ 0.93, logistic
regression), which is intergenic and ﬂanked by TICAM1 and
PLIN3. It is linked to rs7255265 (r2¼ 0.68, D0 ¼ 0.9, Supplemen-
tary Table 18), which is located in an exon of TICAM1 and
has predicted enhancer activity in keratinocytes. TICAM1 is an
intracellular toll-like receptor(TLR) adaptor molecule involved in
innate immunity; moreover, it acts as a pro-apoptotic tumour
suppressor by mediating the interaction between TLR-3
and caspase-8 in some malignancies, including melanoma22.
PLIN3 encodes a cytosolic protein that binds to the GTPase
RAB9, a member of the RAS oncogene family23. Overexpression
of PLIN3 has been linked to cervical carcinoma24.
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Figure 2 | Gene expression analysis for novel BCC susceptibility loci.
Processed microarray expression data were obtained from Gene Expression
Omnibus (GSE53462, blue, and GSE7553, orange). Transcript levels in BCC
samples were compared to levels in normal skin controls via Geo2R. Three
genes—FOXP1, TNS3 and CASC15—were signiﬁcantly upregulated in BCC
relative to normal skin (Po0.05, linear models for microarray analysis) in
both data sets.
Table 3 | Stage 2 subset analysis of novel BCC risk variant rs191177147 (3q28, LPP) in different hair colour subgroups.
Hair colour b s.e. P N Int P-value
Whole set 0.097 0.03 1.0 10 3 17044 0.0002
Red and blonde 0.008 0.062 9.0 10 1 2449
Light brown 0.123 0.047 8.4 10 3 5793
Dark brown and black 0.198 0.042 2.9 10 6 7611
‘b’ refers to effect size, ‘s.e.’ to standard error, ‘P’ to P-value (generated via logistic regression), ‘N’ to sample size, and ‘Int’ to interaction.
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The ﬁfth immune-related SNP, rs9267650 at 6p21.3 (P¼ 1.1
10 8, OR¼ 1.17, logistic regression), lies 0.5 kb downstream of
NEU1, which encodes a lysosomal enzyme implicated in
many diverse processes, including activation of TLRs25,
wound healing26,27 and suppression of ovarian carcinoma28.
Finally, rs11993814 at 8q21.13 (P¼ 1.1 10 12, OR¼ 0.91,
logistic regression), located 9 kb upstream of ZBTB10, is an
eQTL in two tissues and is in LD with rs6998967 (r2¼ 0.6,
D0 ¼ 1.0), associated with late-onset myasthenia gravis29. ZBTB10
encodes a zinc ﬁnger transcription factor involved in regula-
ting the expression of Interleukin-10 through suppression of
Sp129–31. Abnormal interaction between ZBTB10 and Sp1 is seen
in several different cancer cell lines, with ZBTB10 consis-
tently exhibiting tumour-suppressing activity32. All together,
these ﬁndings implicate a number of immune regulatory loci in
BCC susceptibility.
Four of our novel susceptibility loci are associated with tumour
progression. rs2116709 at 3p13 (P¼ 5.7 10 16, OR¼ 0.91,
logistic regression) resides within an intron of FOXP1, a
transcription factor that, in addition to regulating organ
development, acts as a tumour suppressor in some cancers
(for example, prostate33) and as an oncoprotein in others
(for example, oesophagus34). It is overexpressed in oesophageal
cancer and many types of lymphomas, including cutaneous
B-cell lymphomas34,35. Similarly, we found that FOXP1 is
signiﬁcantly overexpressed in BCC as compared with normal
skin controls. Our ﬁndings suggest a role for FOXP1 in BCC
development.
rs73183643 at 7q22.1 (P¼ 1.3 10 13, OR¼ 0.91, logistic
regression) is located 40 kb upstream of CUX1, which encodes a
homeodomain-containing transcription factor involved in cell
proliferation and differentiation. Both in vitro and in vivo studies
have shown that CUX1 promotes tumorigenesis in a range of
neoplasms, including melanoma and pancreatic cancer, by
increasing cell motility and inhibiting apoptosis36,37.
Another tumorigenesis-related SNP, rs7776701 at 7p12.3
(P¼ 2.0 10 8, OR¼ 0.94, logistic regression), lies within an
intron of TNS3 and has enhancer activity in 14 tissues, including
keratinocytes. This SNP is in LD with rs56232506 (r2¼ 0.76,
D0 ¼ 0.99), also intronic to TNS3 and associated with prostate
cancer38. Tensin-3, the cytosolic protein product of TNS3,
connects transmembrane proteins to cytoskeletal elements and
inﬂuences cell migration39. Studies of human metastatic
melanoma, non-small cell lung cancer and breast cancer cell
lines demonstrate that reduced expression of TNS3 corresponds
to dramatic inhibition of cell proliferation and migration,
suggesting that TNS3 is an oncogene39. This idea is consistent
with our expression analysis, in which TNS3 was signiﬁcantly
upregulated in BCC.
The fourth SNP in this category, rs4710154 at 6q27 (P¼ 1.1
10 8, OR¼ 1.08, logistic regression), lies 17 kb downstream of
MIR3939, which codes for microRNA 3939. Despite its proximity
to MIR3939, rs4710154 is an eQTL for RNASET2 in 11 tissues,
including sun-exposed skin (P¼ 4.7 10 19, GTEx V6 analysis)
and non-sun-exposed skin (P¼ 1.1 10 7, GTEx V6 analysis)11.
This SNP is linked to rs9355610 (r2¼ 0.89, D0 ¼ 0.99,
Supplementary Table 19), associated with Grave’s disease and
Hashimoto’s thyroiditis40; rs9355610 is also an eQTL for
RNASET2 in sun-exposed (P¼ 1.0 10 1, GTEx V6 analysis)
and non-sun-exposed skin (P¼ 1.6 10 8, GTEx V6 analysis)11.
RNASET2 encodes ribonuclease T2, an evolutionarily conserved,
ubiquitous RNase that inhibits cell proliferation (via stimulation
of immune cells) and mediates cellular stress responses41.
Accordingly, this enzyme has tumour suppressor activity in
many cancer lines, including melanoma42, and has demonstrated
pro-apoptotic activity in keratinocytes43.
Interestingly, two of the 14 novel susceptibility variants reside
near or within long non-coding RNA genes. rs2776353 at 21q22.3
(P¼ 2.0 10 14, OR¼ 0.91, logistic regression) is located
10 kb upstream of LINC00111, while rs2294214 (P¼ 3.1 10 8,
OR¼ 1.07, logistic regression) lies within an intron of CASC15
(also known as LINC00340); both SNPs have predicted enhancer
and promoter activity in keratinocytes. A recent study compared
the expression of long non-coding RNAs in BCC samples to
that of normal skin controls and found that CASC15 was
overexpressed in BCC44. Overexpression of CASC15 has also
been implicated in melanoma progression and metastasis45. Our
analysis of independent BCC expression data conﬁrmed
signiﬁcant upregulation of CASC15 in BCC, further implicating
this gene in BCC development.
In addition to conﬁrming the previously reported association
of ﬁve pigmentation loci with BCC, we identiﬁed a novel
susceptibility locus—rs10810657 at 9p22.2 (P¼ 1.5 10 17,
OR¼ 0.90, logistic regression)—that may also inﬂuence pigmen-
tation. rs10810657, located 14 kb upstream of BNC2, reached
genome-wide signiﬁcance in the meta-analysis and is an eQTL for
BNC2 in blood (Table 2). This SNP is in LD with rs12350739
(r2¼ 0.87, D0 ¼ 0.99, Supplementary Table 20), associated with
human skin pigmentation via regulation of BNC2 transcription in
melanocytes, and rs62543565 (r2¼ 0.7, D0 ¼ 0.87), associated
with the age-related development of facial pigmented spots46,47.
rs10810657 is also linked to rs2153271 (r2¼ 0.9, D0 ¼ 0.99),
which is intronic to BNC2 and associated with freckling48. BNC2
codes for basonuclin 2, a protein thought to function both as an
mRNA-processing enzyme and a transcription factor46. It is
expressed in melanocytes and, to a lesser extent, keratinocytes,
with higher expression levels corresponding to darker skin
pigmentation46.
In summary, this two-stage meta-analysis represents the largest
GWAS for BCC and identiﬁed 14 novel susceptibility loci with
roles in telomere maintenance, immune regulation and tumour
progression. Further investigation of these loci will improve our
understanding of BCC pathogenesis and improve our ability to
prevent these common tumours.
Methods
Stage 1 study design and population. 23andMe Inc. (Mountain View, CA), a
genetics company, provided free access to anonymized genetic and phenotypic
information for stage 1 of this GWAS. All information came from 23andMe
research participants who provided informed consent to participate in research, in
accord with 23andMe’s human subjects protocol (reviewed and approved by
Ethical and Independent Review Services, an AAHRPP accredited IRB). 23andMe
gathers genetic information by genotyping sample material provided by its research
participants; phenotypic information is collected via research participant responses
to online surveys. Inclusion and exclusion criteria are discussed below. Sample sizes
for cases and controls were not predetermined as the intention was to maximize the
number of subjects in both groups; hence, all subjects passing inclusion and
exclusion criteria were included, which resulted in 12,945 BCC cases and
274,252 controls.
Stage 1 genome-wide association analysis. Association analysis for stage 1 was
performed using logistic regression, assuming an additive model for allelic effects.
The analysis was adjusted for age, sex and population stratiﬁcation (using the ﬁrst
ﬁve principal components), generating the following model:
BCC diagnosis  ageþ sexþ pc:0þ pc:1þ pc:2þ pc:3þ pc:4þ genotype
ð1Þ
The association test P-value was computed using a likelihood ratio test. Results
for the X chromosome were computed similarly, with male genotypes coded as if
they were homozygous diploid for the observed allele. Additionally, test statistics
were adjusted for genomic control to correct for residual population stratiﬁcation
persisting after principal component analysis; the genomic control inﬂation factor
was 1.085 (computed from the median P-value for results that passed quality
control).
Genome-wide association analysis generated a set of index SNPs. The index
SNPs show information for the most-associated SNP in each associated region. We
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deﬁne regions of interest by identifying SNPs with Po10 5, then grouping these
into intervals separated by gaps of at least 250 kb, and choosing the SNP with
smallest P within each interval.
Stage 1 genotyping and quality control. Samples were genotyped on one of four
genotyping platforms. The V1 and V2 platforms were variants of the Illumina
HumanHap550þ BeadChip, including about 25,000 custom SNPs selected by
23andMe, with a total of about 560,000 SNPs. The V3 platform was based on the
Illumina OmniExpressþ BeadChip, with custom content to improve the overlap
with our V2 array, with a total of about 950,000 SNPs. The V4 platform in current
use is a fully custom array, including a lower redundancy subset of V2 and V3
SNPs with additional coverage of lower-frequency coding variation, and about
570,000 SNPs. Samples that failed to reach 98.5% call rate were re-analysed.
Individuals whose analyses failed repeatedly were re-contacted by 23andMe to
provide additional samples, as is done for all 23andMe research participants.
Individuals were only included if they had 497% European ancestry, as
determined through an analysis of local ancestry49. Brieﬂy, this analysis ﬁrst
partitions phased genomic data into short windows of about 100 SNPs. Within
each window, a support vector machine is used to classify individual haplotypes
into one of 31 reference populations. The support vector machine classiﬁcations are
then fed into a hidden Markov model (HMM) that accounts for switch errors and
incorrect assignments, and gives probabilities for each reference population in each
window. Finally, simulated admixed individuals are used to recalibrate the HMM
probabilities so that the reported assignments are consistent with the simulated
admixture proportions. The reference population data are derived from public data
sets (the Human Genome Diversity Project, HapMap and 1000 Genomes), as well
as 23andMe research participants who have reported having four grandparents
from the same country.
A maximal set of unrelated individuals was chosen for each analysis using a
segmental identity-by-descent (IBD) estimation algorithm50. Individuals were
deﬁned as related if they shared more than 700 cM IBD, including regions where the
two individuals share either one or both genomic segments identical-by-descent.
This level of relatedness (roughly 20% of the genome) corresponds approximately to
the minimal expected sharing between ﬁrst cousins in an outbred population.
Participant genotype data were imputed against the March 2012 ‘v3’ release of
1000 Genomes reference haplotypes51. Data for each genotyping platform were
phased and imputed separately. First, Beagle52 (version 3.3.1) was used to phase
batches of 8000–9000 individuals across chromosomal segments of no more than
10,000 genotyped SNPs, with overlaps of 200 SNPs. SNPs with Hardy-Weinberg
equilibrium Po10 20, call rateo95%, or with large allele frequency discrepancies
compared to European 1000 Genomes reference data were excluded. Frequency
discrepancies were identiﬁed by computing a 2 2 table of allele counts for
European 1000 Genomes samples and 2000 randomly sampled 23andMe research
participants with European ancestry, and identifying SNPs with a chi-squared
Po10 15. Each phased segment was imputed against all-ethnicity 1000 Genomes
haplotypes (excluding monomorphic and singleton sites) using Minimac253, using
5 rounds and 200 states for parameter estimation.
For the non-pseudoautosomal region of the X chromosome, males and females
were phased together in segments, treating the males as already phased; the
pseudoautosomal regions were phased separately. Males and females were then
imputed together using minimac, as with the autosomes, treating males as
homozygous pseudo-diploids for the non-pseudoautosomal region.
For quality control of genotyped GWAS results, SNPs that were only genotyped
on the ‘V1’ platform were ﬂagged due to small sample size, and SNPs on chrM or
chrY because many of these are not currently called reliably. Using trio data, SNPs
that failed a test for parent-offspring transmission were also ﬂagged; speciﬁcally,
the child’s allele count was regressed against the mean parental allele count, and
SNPs with ﬁtted bo0.6 and Po10 20 for a test of bo1 were ﬂagged. SNPs with
a Hardy-Weinberg Po10 20 in Europeans, or a call rate of o90%, were also
ﬂagged. Genotyped SNPs were also tested for genotype date effects, and SNPs with
Po10 50 by analysis of variance of SNP genotypes against a factor dividing
genotyping date into 20 roughly equal-sized buckets were ﬂagged.
For imputed GWAS results, SNPs with avg.rsqo0.5 or min.rsqo0.3 in any
imputation batch were ﬂagged, as well as SNPs that had strong evidence of an
imputation batch effect. The batch effect test was an F test from an analysis of
variance of the SNP dosages against a factor representing imputation batch; results
with Po10 50 were ﬂagged. Prior to GWAS, the largest subset of the data passing
these criteria was identiﬁed for each SNP, based on their original genotyping
platform—either v2þ v3þ v4, v3þ v4, v3, or v4 only—and association test results
were computed for whatever was the largest passing set. As a result, there were no
imputed results for SNPs that failed these ﬁlters.
When choosing between imputed and genotyped GWAS results, if either the
imputed test passed quality control, or a genotyped test was unavailable, the
imputed result was reported; otherwise, the genotyped result was reported. For tests
using imputed data, imputed dosages were used rather than best-guess genotypes.
Across all results, logistic regression results that did not converge due to
complete separation, identiﬁed by abs (effect)410 or stderr410 on the log odds
scale, were ﬂagged. Linear regression results for SNPs with MAFo0.1% were also
ﬂagged, since tests of low frequency variants can be sensitive to violations of the
regression assumption of normally distributed residuals20,54,55.
Stage 1 associations using nearest genotyped SNP. To assess the effect of
imputation, we analysed the association between the nearest genotyped SNP at
each locus and BCC, and then compared this association to that from the original
imputed SNP. The genotyped results are consistent with the imputed results albeit
slightly less signiﬁcant.
Stage 1 subset analyses. Subset analysis by age and gender was performed for the
genome-wide signiﬁcant index SNPs in stage 1. For age-based analysis, the stage 1
cohort was divided into four age intervals with similar effective sample sizes based
on case and control sample counts. Association test results were then computed
within each of these age intervals for the 28 SNPs. The interaction between
genotype effect and age interval was also calculated. For all these association tests,
we used the same covariates used in stage 1: age, sex and ﬁve principal components.
Thus, association tests within a speciﬁc age interval were still adjusted for age as a
continuous covariate. For gender analysis, we compared effect sizes estimated in
men versus effect sizes estimated in women for the 28 SNPs. We also performed
logistic regression separately in the male and female subsets, and calculated
P-values from a likelihood ratio test for adding a gender by genotype interaction to
the full logistic regression models. For melanoma subset analysis, association tests
for BCC were computed separately in melanoma controls and melanoma cases.
Stage 1 phenotype categorization. 23andMe identiﬁed BCC cases by using
research participants’ self-reported answers to online questionnaires. Subjects who
answered ‘Yes’ and/or selected BCC from a dropdown menu in response to at least
one of the following questions were deﬁned as cases: ‘Have you ever been diag-
nosed by a doctor with basal cell carcinoma?’, ‘What type of skin cancer did you
have? Please check all that apply.’, ‘What type of skin cancer or cancers have you
been diagnosed with? Please check all that apply.’ ‘Have you ever been diagnosed
with basal cell carcinoma?’ ‘Have you ever been diagnosed or treated for any of the
following conditions?’ Controls were deﬁned as subjects who answered ‘No’ and
did not select BCC from any relevant dropdown menus. In addition, subjects who
answered ‘No’ to at least one of the following questions (and ‘Yes’ to none) were
deﬁned as controls: ‘Have you ever been diagnosed with cancer, including skin
cancer or cancerous moles?’, ‘Has a doctor ever told you that you have a type of
cancer?’, ‘Have you ever been diagnosed or treated with any of the following
conditions?’ Among the samples with imputed genotypes, 23andMe has 12,945
BCC cases and 274,252 controls.
Sensitivity and speciﬁcity of stage 1 self-reported data. To assess the validity of
self-reported phenotypic data in stage 1, 23andMe surveys (pertaining to skin
cancer history and pigmentation) were randomly administered to patients seen in
Stanford outpatient clinics. The survey answers were then compared to medical
records to assess for accuracy with respect to BCC diagnosis to determine the
sensitivity and speciﬁcity of the survey responses. P-values were determined using
chi-square analysis. This sub-study was approved by the Stanford University
Institutional Review Board with a waiver of documentation of informed consent.
Stage 2 study design and population. The Nurses’ Health Study was established
in 1976, when 121 700 female registered nurses between the ages of 30 and 55 years
residing in 11 larger US states completed and returned an initial self-administered
questionnaire on their medical histories and baseline health-related exposures.
Biennial questionnaires with collection of exposure information on risk factors
have been collected prospectively. Every 2 years, along with exposures, outcome
data with appropriate follow-up of reported disease events are collected. Overall,
follow-up has been high; after more than 20 years,B90% of participants continue
to complete questionnaires. From May 1989 through September 1990, we collected
blood samples from 32,826 participants in the NHS. Information on BCC devel-
opment was ﬁrst collected in the 1984 questionnaire.
The Health Professionals Follow-up Study (HPFS) was established in 1986
when 51,529 men from all 50 US states in health professions (dentists, pharmacists,
optometrists, osteopath physicians, podiatrists and veterinarians) aged 40–75 years
answered a detailed mailed questionnaire. The average follow-up rate for this
cohort over 10 years is 490%. On each biennial questionnaire, we obtained
disease- and health-related information. Between 1993 and 1994, 18,159 study
participants provided blood samples by overnight courier. Information on BCC
development was ﬁrst collected in the 1986 questionnaire.
The protocol for this study was approved by the Institutional Review Board at
Brigham and Women’s Hospital and the Harvard School of Public Health. All of
the participants provided informed consent. As in stage 1, all subjects passing
inclusion and exclusion criteria were included, resulting in 4,242 BCC cases and
12,802 controls; sample sizes were not predetermined.
Stage 2 genotyping and quality control. There were 18 GWAS data sets from the
NHS and HPFS as nested case-control studies with cleaned genotype data available.
We combined these data sets into three complied data sets based on their genotype
platform type: Affymetrix, Illumina HumanHap series or Illumina Omni Express.
The Affymetrix data set was comprised of data on the Affy 6.0 platform (NHS-type
2 diabetes, NHS-coronary heart disease, HPFS-type 2 diabetes, HPFS-coronary
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heart disease). The Illumia HumanHap data set was comprised of several plat-
forms: Illumina 550K (NHS-breast cancer, NHS-Pancreas cancer, HPFS-pancreas
cancer), Illumina 610Q (NHS-kidney stone, HPFS-kidney stone, HPFS-prostate
cancer) and Illumina 660 (NHS-glaucoma, HPFS-glaucoma). The Illumina Omni
Express data set contained only studies genotyped on the Omni Express platform
(NHS-endometrial cancer, NHS-colon cancer, NHS-mammographic density,
NHS-gout, HPFS-colon, HPFS-gout).
We combined the individual data sets that were genotyped on the same
platform, removing any SNPs that were not in all studies and with a missing call
rate45%, and ﬂipping strands where appropriate to create a ﬁnal compiled data
set. This resulted in 668,283 SNPs in the Affymetrix data set, 459,999 SNPs in the
Illumina HumanHap data set and 565,810 SNPs in the Illumina Omni Express data
set. Analyses were restricted to subjects with self-reported European ancestry.
Genetic principal components were calculated using sets of independent SNPs
(12,000–33,000 SNPs depending on platform). Subjects who did not cluster with
other self-identiﬁed Europeans based on the top ﬁve principal components were
also excluded.
We then ran a pairwise IBD analysis for each combined data set to detect
duplicate and related individuals based on resulting Z scores. If 0pZ0p0.1
and 0pZ1p0.1 and 0.9 pZ2p1.1 then a pair was ﬂagged as being identical
twins or duplicates. Pairs were considered full siblings if 0.17pZ0p0.33 and
0.4pZ1p0.6 and 0.17pZ2p0.33. Half siblings or avunculars were deﬁned
as having 0.4pZ1p0.6 and 0pZ2p0.1. Some of the duplicates ﬂagged in this
step were expected, having been genotyped in multiple data sets and hence having
the same cohort IDs. In this case, one of each pair was randomly chosen for
removal from the data set. Instances where pairs were ﬂagged as unexpected
duplicates with the different cohort IDs, but pairwise genotype concordance
rate40.999, resulted in removal of both individuals from the pair. Related
individuals (full sibs, half sibs/avunculars) were not removed from the ﬁnal data
sets. In the Affymetrix data set, 167 individuals were removed because they were
duplicates or were ﬂagged for removal from secondary genotype data cleaning,
leaving a total of 8065 individuals. Of the 6894 individuals originally in the
Illumina data set, 107 were removed because they were duplicates or ﬂagged for
removal in the genotyping step, leaving 6787 IDs. In addition, eight pairs of
individuals were ﬂagged as related. In the Omni express data set, there were 5956
individuals at the start, with 39 IDs to remove leaving 5917 IDs and 5 pairs of
related IDs.
After removing duplicate IDs and ﬂagging related pairs of IDs, we used
eigenstrat to run PCA analysis on each compiled data set, removing one member
from each ﬂagged pair of related individuals. For Affymetrix and Illumina
HumanHap, we used approximately 12,000 SNPs that were ﬁltered to ensure low
pairwise LD56. For the OmniExpress data set we used approximately 33,000 SNPs
that were similarly ﬁltered. We plotted the top eigenvectors using R and examined
the plots for outliers.
Finally as a quality control check, we ran logistic regression analyses using each
individual study’s controls as ‘cases’ and the rest of the studies controls as
‘controls’. For example, in the Illumina Omni Express data set, we ran regressions
of NHS-gout controls considered as ‘cases’ versus the HPFS-gout, NHS-
endometrial cancer, NHS-colon cancer, NHS-mammographic density and
HPFS-colon cancer. We then ran regressions with each of the other study controls
as ‘cases’ versus all of the rest of the controls. We looked for P values of genome-
wide signiﬁcance (Po10 8) and examined QQ plots to determine if any
SNPs were ﬂagged as signiﬁcant where no SNPs should have been signiﬁcant.
In the Affymetrix data set 100 SNPs were ﬂagged and removed. In the Illumina
HumanHap data set, eight SNPs had Po10 8 in any of the QC regressions
and were removed. No SNPs in the Illumina Omni Express data set had
P-valueso10 8 hence no additional SNPs needed to be removed. After the data
sets were combined and appropriate SNP and ID ﬁlters applied, the complied data
sets were imputed.
Using combined GWAS genotypes on each genotyping platform and the
1000 Genomes Project ALL Phase I Integrated Release Version 3 Haplotypes
excluding monomorphic and singleton sites (2010-11 data freeze, 2012-03-14
haplotypes) as reference panel, we imputed the genotypes of markers in the
1000 Genomes Project for 8065 samples in Affymetrix data set, 6787 samples
in Illumina HumanHap data set and 5917 samples in Illumina Omni Express
data set.
SNP genotypes were imputed in three steps. First, genotypes on each
chromosome were split into chunks to facilitate windowed imputation in parallel
using ChunkChromosome (v.2011-08-05) (http://genome.sph.umich.edu/wiki/
ChunkChromosome). Then each chunk of chromosome was phased using MACH
(v.1.0.18.c) (http://www.sph.umich.edu/csg/abecasis/MaCH/index.html). In the
ﬁnal step, Minimac (v.2012-08-15) (http://genome.sph.umich.edu/wiki/Minimac)
was used to impute the phased genotypes to approximately 31 million markers in
the 1000 Genomes Project51.
Sensitivity analysis in stage 2. Sensitivity analysis for ﬁve SNPs—IRF4
rs12203592, KRT5 rs11170164, PLIN3 rs10425559, NEU1 rs9267650 and EXOC2
rs12210050—using high imputation quality subsets was performed. Concordance
for two SNPs (rs12916300 and rs35407) was compared between stage 2 imputed
data and directly genotyped data among the overlapping samples of 251 controls
and 280 cases. Direct genotyping was also performed for rs9275642 and rs1050529
in a subset of BCC cases and controls within NHS. The total sample size is 1204
with 661 cases and 543 controls.
Stage 2 phenotype categorization. Participants in both NHS and HPFS cohorts
reported new BCC diagnosis biennially. Eligible cases in the NHS and HPFS
consisted of participants with self-reported BCC any time after baseline up to the
2012 follow-up cycle for both cohorts. Samples free of BCC were controls in this
study. In the three compiled data sets, samples without information on BCC
diagnosis were excluded. Furthermore, all BCC cases with melanoma were also
excluded. Among the samples with imputed genotypes, we have 1777 BCC cases
and 5411 controls in Affymetrix data set, 1268 BCC cases and 3685 controls in
Illumina HumanHap data set and 1197 BCC cases and 3706 controls in Illumina
Omni Express data set totalling 4242 BCC cases and 12,802 controls.
Validity of stage 2 self-reported data. The identiﬁcation of BCC cases in stage 2
was based on self-report without pathological conﬁrmation. Because the partici-
pants in the cohorts were nurses and other health professionals, the validity of their
reports was expected to be high and has been proven in validation studies: 490%
conﬁrmed by histopathology records57–59. In addition, previous studies of BCC in
the NHS using self-reported cases identiﬁed both constitutional and sun-exposure
risk factors as expected, such as lighter pigmentation, less childhood and adolescent
tanning tendency, higher tendency to sunburn, and tanning salon attendance58,60.
Moreover, in our previous study of BCC using the same cohorts as this study (NHS
and HPFS), we conﬁrmed the MC1R gene (a well-established pigmentation gene)
as the most promising locus of BCC risk4. In addition, we identiﬁed many other
pigmentation SNPs (for example, rs12203592 at IRF4, rs1408799 at TYRP1 and
rs12913832 at HERC2) in our data set with signiﬁcant associations with BCC4.
These genetic and non-genetic data together suggest that the bias due to self-report
of BCC is likely to be minimal in our study.
Stage 2 genome-wide association analysis. We used ProbABEL software to test
the GWAS association between minor allele counts and BCC risk using imputed
dosage data. We performed logistic regression analysis under an additive model
with adjustment for age, sex, BCC history and the ﬁrst ﬁve principal components,
generating the following model:
BCC diagnosis  ageþ sexþ pc:1þ pc:2þ pc:3þ pc:4þ pc:5þ genotype
ð2Þ
These principal components were calculated for all individuals on the basis of
approximately 10,000 unlinked markers using the EIGENSTRAT software61.
Associations in each component GWAS set (Affymetrix, Illumina HumanHap
series and Illumina Omni Express) were combined in an inverse-variance-weighted
meta-analysis using the METAL software.
Phenotype and environmental factors. The amount of UV exposure based on
residence location in 1986 was coded as a continuous variable. Information on
pigmentation traits was collected from prospective questionnaires in both the NHS
and HPFS using similar wording. We regressed ordinal coding for natural hair
colour (1—red, 2—blonde, 3—light brown, 4—dark brown or black), tanning
ability during adolescence (1—tans without burning (none/some redness only),
2—burns then tans, 3—burns/peels (painful burn with blisters)) and number
of blistering sunburns (1¼ never, 2¼ 1-2 times, 3¼ 3–5 times, 4¼ 6 times and
above).
Statistical models for pigmentation and UV exposure. To clarify the
inﬂuence of pigmentation traits on our associations, we additionally adjusted
for these traits (hair colour, tanning ability during adolescence and number
of blistering sunburns) in individual studies with ProbABEL. Associations in
each component GWAS set (Affymetrix, Illumina HumanHap series and Illumina
Omni Express) were combined in the same meta-analysis using the METAL
software.
The primary gene-risk factor interaction analytic model included each SNP and
risk factor (UV exposure or pigmentation traits) and an SNP risk factor
interaction term, as well as age, sex and the ﬁrst ﬁve principal components as
covariates:
BCC diagnosis  ageþ sexþ risk factorþ pc:1þ pc:2þ pc:3þ pc:4þ
pc:5þ genotypeþ genotyperisk factor ð3Þ
The logistic regression analyses within each platform were conducted with
ProbABEL. Associations in each component GWAS set (Affymetrix, Illumina
HumanHap series and Illumina Omni Express) were combined in an inverse-
variance-weighted meta-analysis using the METAL software.
Meta-analysis. For each SNP, meta-analysis was conducted to combine stage 1
and stage 2 results. Heterogeneity of per-SNP effect sizes in studies contributing to
stage 1, stage 2 and the overall meta-analysis was assessed and ﬁxed effects meta-
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12510 ARTICLE
NATURE COMMUNICATIONS | 7:12510 |DOI: 10.1038/ncomms12510 | www.nature.com/naturecommunications 7
analysis was conducted. The same method as in stage 1 was used to generate a set
of index SNPs within each associated region. Top SNPs with Po5 10 8 were
ﬁnally reported. All R2 and D’ between individual SNPs were calculated based on
the 1000 Genomes Pilot 1 data set, CEU Population (http://www.broadin-
stitute.org/mpg/snap/ldsearchpw.php)62.
Proportion of familial relative risk. We have used the formula for calculating the
proportion of FRR as outlined by the Cancer Oncological Gene-environment
Study (http://www.nature.com/icogs/primer/common-variation-and-heritability-
estimates-for-breast-ovarian-and-prostate-cancers/#70) as described previously63.
The odds ratios derived from our meta-analysis of stages 1 and 2 are assumed to be
relative risks. We estimated the proportion of the FRR explained by each SNP
(FRRsnp) as:
FRRsnp ¼ pr2 þ q
 
= prþ qð Þ2 ð4Þ
Here, the risk allele and alternative allele frequencies are p and q, respectively,
and r is the odds ratio for the risk allele. Allele frequencies derived from the
1000 Genomes Project European population data. Assuming that the loci
combine multiplicatively and are not in LD, the combined effect of all loci is
given by:
lT ¼
Y
k
lk ð5Þ
Here, the product is across all loci. The proportion of the familial relative risk
attributable to the SNPs, on a log scale, is then given by:
log lTð Þ=log lPð Þ ð6Þ
In this equation, lP is the familial relative risk observed in epidemiological studies.
lP is 2.6-fold for BCC60,64.
Regulatory function of novel variants. For each novel BCC susceptibility variant,
we searched for evidence of regulatory function using recently updated HaploReg
version 4 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php)65,66.
We queried each rsID and extracted data from ENCODE Project Consortium
2011–2012 on closest annotated gene, ChIP-Seq transcription factor binding,
DNaseI hypersensitivity sites, and enhancer and promoter chromatin segmentation
states67–69. We also extracted data from Roadmap Epigenomics Consortium 2015
on enhancer and promoter chromatin segmentation states, speciﬁcally using the
following states: 15-state HMM, 25-state HMM, H3K4me1, H3K4me3, H3K27ac
and H3K9ac70. We particularly focused on enhancer and promoter annotations
that referenced normal human epidermal keratinocytes (NHEK) and primary
foreskin keratinocytes. Finally, we used HaploReg v4 to extract eQTL data for each
variant, as version 4 is updated with cis eQTL data from the GTEx pilot analysis
and other studies11. We made special note of variants that were eQTLs in skin
tissue.
Gene expression analysis. Processed gene-expression data for BCC and
normal skin (GSE53462 and GSE7553) were obtained from the GEO
(http://www.ncbi.nlm.nih.gov/geo/)71–73. Fifteen BCC samples and ﬁve
controls were included for GSE7553; for GSE53462, nine ‘classic-type’ BCC
samples were included, along with ﬁve controls. Each gene of interest was
selected by its proximity to one of the 14 novel risk variants; however, if a
variant was an eQTL in skin tissue for a more distant gene, then this gene was
chosen instead. For each data set, Geo2R, which employs a linear-based model
for microarray analysis, was utilized to compare gene expression between BCC
and normal skin controls74. Signiﬁcant results were deﬁned as instances of
differential gene expression (in BCC tissue relative to control) reaching
Po0.05 in both data sets.
Regional association and forest plots. Regional plots of –log10 (P values)
were generated using Locus Zoom75. Where pairwise LD measures are given,
using LD data from the March 2012 release of 1000 Genomes data. To preserve
detail, results with Po10 100 are set to 10 100. In the plots, an ‘o’ symbol
indicates a genotyped SNP and a ‘þ ’ indicates an imputed SNP. Colour indicates
strength of LD with the index SNP. Forest plots were generated using the R forest
plot package (https://cran.r-project.org/web/packages/forestplot/forestplot.pdf)76.
Power calculations. Power was computed according to Freidlin et al.77. To
account for misclassiﬁcation, expected genotype frequencies in study cases were
replaced with a mixture of genotype frequencies in true cases and in true controls.
Power was plotted as a function of odds ratio for detecting a variant with minor
allele frequency 0.1, based on the GWAS sample size and with hypothetical
misclassiﬁcation rates of 0, 10 and 20% (where the speciﬁed fraction of study cases
are misclassiﬁed controls).
Data availability. GWAS data from 23andMe and Nurses ‘Health/Health
Professionals’ Study have not been deposited in public repositories, as consent for
this was not obtained in the study protocols. The pre-computed rankings and
P-values for SNPs included in the stage 1 GWAS are available upon request by
contacting D.A.H. at dhinds@23andMe.com. Pre-computed rankings and P-values
for the top 10,000 SNPs included in the stage 2 GWAS are freely available by
contacting www.channing.harvard.edu/nhs. Processed gene-expression data for
BCC and normal skin are freely available from GEO (http://www.ncbi.nlm.nih.gov/
geo/) using the accession numbers GSE53462 (ref. 72) and GSE7553
(ref. 73). Any additional data (beyond those included in the main text and
Supplementary Information) that support the ﬁndings of this study are available
from the corresponding author upon request.
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